Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Short-term Investments: 2012-2024

Historic Short-term Investments for Capricor Therapeutics (CAPR) over the last 10 years, with Dec 2024 value amounting to $140.2 million.

  • Capricor Therapeutics' Short-term Investments rose 374.77% to $79.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.1 million, marking a year-over-year increase of 374.77%. This contributed to the annual value of $140.2 million for FY2024, which is 465.60% up from last year.
  • According to the latest figures from FY2024, Capricor Therapeutics' Short-term Investments is $140.2 million, which was up 465.60% from $24.8 million recorded in FY2023.
  • Over the past 5 years, Capricor Therapeutics' Short-term Investments peaked at $140.2 million during FY2024, and registered a low of $24.8 million during FY2023.
  • Over the past 3 years, Capricor Therapeutics' median Short-term Investments value was $31.8 million (recorded in 2022), while the average stood at $65.6 million.
  • In the last 5 years, Capricor Therapeutics' Short-term Investments declined by 22.08% in 2023 and then spiked by 465.60% in 2024.
  • Over the past 3 years, Capricor Therapeutics' Short-term Investments (Yearly) stood at $31.8 million in 2022, then fell by 22.08% to $24.8 million in 2023, then surged by 465.60% to $140.2 million in 2024.